Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
|ClinicalTrials.gov Identifier: NCT00110929|
Recruitment Status : Completed
First Posted : May 17, 2005
Last Update Posted : April 23, 2010
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Disease||Drug: AMG 073||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||850 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)|
|Study Start Date :||November 2002|
- Examine PTH and Ca x P control when cinacalcet is administered in the setting of flexible dosing of vitamin D sterols.
- Examine safety and tolerability of cinacalcet.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00110929